RPG Life Sciences Q1 FY27 Revenue up 15.8%, EBITDA up 17.9%
RPG Life Sciences reported strong unaudited financial results for Q1 FY27, with revenue from operations increasing 15.8% year-on-year to ₹195.7 crore. EBITDA grew 17.9% to ₹48.0 crore, and the EBITDA margin expanded by 40 basis points to 24.5%. The Domestic Formulations business outperformed the Indian pharma market, growing 14.8% against the market's 11.6%, leading the company to enter the 'Top 50 Indian Pharma Companies'. International Formulations registered 7.7% growth, and the API business saw a significant 35.6% increase. Managing Director Ashok Nair emphasized the strong start, market-beating performance, and strategic focus on international expansion and API operations for sustained long-term growth.
Key Highlights
- Revenue grew 15.8% to ₹195.7 Cr in Q1 FY27.
- EBITDA increased 17.9% with 24.5% margin.
- Domestic Formulations grew 14.8%, outperforming IPM.
- Company entered Top 50 Indian Pharma Companies.
- API business showed strong 35.6% growth.
Price Impact
More from RPGLIFE